Clinical trials: Semaglutide, completed
Diabetes Mellitus, Type 2
A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
This study looks at how a new medicine insulin icodec helps in reducing blood sugar levels when given along with semaglutide in patients with type 2 diabetes.
- Trial name
- NCT05813912
- Testing
- Insulin Icodec, Semaglutide
- Where
- 39 sites in Czechia, Malaysia and 3 more
- Volunteers
- 148 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets
Participants in the study, will receive the study drug once daily for 10 days in tablet form for oral (by mouth) intake. On day 1 to 5 the tablet will contain 3 mg semaglutide, and on day 6-10 the tablet will contain 7 mg…
- Trial name
- NCT04817644
- Testing
- Oral semaglutide
- Where
- 2 sites in United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause
Novo Nordisk is developing a combination therapy with the investigational drug NNC0480-0389 and an already approved medicine called "semaglutide" for the treatment of type-2 diabetes (T2D).
- Trial name
- NCT05153564
- Testing
- Semaglutide 1.34 mg/mL, Semaglutide 3.0 mg/mL, NNC0480-0389 10 mg/mL
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight.
- Trial name
- STEP12 (NCT06041217)
- Testing
- Semaglutide
- Where
- 21 sites in China, Taiwan
- Volunteers
- 242 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting.
- Trial name
- NCT03596450
- Testing
- Semaglutide, Standard of care
- Where
- 181 sites in United States, Canada
- Volunteers
- 1,278 people
- Sponsor
- Novo Nordisk A/S
Obesity, Adolescent
Young Adults With Early-onset Obesity Treated With Semaglutide
Introduction: The increasing prevalence of obesity is particularly pronounced among adolescents. Currently available treatment options consist of structured lifestyle interventions.
- Trial name
- RESETTLE (NCT05574439)
- Testing
- TCOC treatment, Semaglutide 3 mg/ml
- Where
- 2 sites in Denmark
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- Signe Torekov
Diabetes, Healthy
Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly
This trial is conducted in Europe. The aim of this trial is to compare the steady-state exposure of semaglutide administered subcutaneously once daily to semaglutide administered subcutaneously once weekly in healthy subjects.
- Trial name
- NCT02557620
- Testing
- semaglutide
- Where
- Germany
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Semaglutide-Induced Gastric Motility, Gastroparesis
Body Surface Gastric Mapping in Patients on Semaglutide
Glucagon-like receptor-1 agonists (GLP-1 RAs), such as Semaglutide (Ozempic), are a class of drugs used for glycemic control in diabetes, and for weight loss and management in obesity.
- Trial name
- NCT06401746
- Testing
- Gastric Alimetry
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- University of Western Sydney
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to evaluate efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD…
- Trial name
- SUSTAIN™ 2 (NCT01930188)
- Testing
- semaglutide, sitagliptin
- Where
- 141 sites in Argentina, Bulgaria and 16 more
- Volunteers
- 1,231 people
- Sponsor
- Novo Nordisk A/S
Weight Loss
Effect of a Low-carbohydrate Diet on Weight Loss in People Using the Injectable GLP-1 Agonist Semaglutide for Weight Loss
The goal of this clinical trial is to determine the effect of a low carbohydrate higher protein diet, modelled after the Atkins program on weight loss, glycemic control, risk markers of cardiovascular disease and body composition…
- Trial name
- NCT07280403
- Testing
- Low Carbohydrate, Low Fat
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- INQUIS Clinical Research
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH).
- Conditions
- Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease
- Trial name
- NCT05877547
- Testing
- Efinopegdutide, Semaglutide
- Where
- 175 sites in United States, Austria and 24 more
- Volunteers
- 381 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®
The purpose of this study is to assess the safety of long-term treatment with Ozempic® in patients with type 2 diabetes mellitus. People will get Ozempic® as prescribed by their doctor. People will be in this study about 3 years.
- Trial name
- NCT04469855
- Testing
- semaglutide
- Where
- 414 sites in Japan
- Volunteers
- 3,217 people
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
This study will compare two different ways of giving cagrilintide and semaglutide for treating overweight and obesity. The medicines will either be given together in 1 injection or as 2 separate injections.
- Trial name
- NCT04940078
- Testing
- Cagrilintide, semaglutide, Cagrilintide and semaglutide
- Where
- 2 sites in Canada, Denmark
- Volunteers
- 40 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Overweight
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials.
- Conditions
- Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk
- Trial name
- TIRZSEMA-CVOT (NCT07096063)
- Testing
- Tirzepatide, Dulaglutide, Semaglutide
- Where
- United States
- Volunteers
- 887,132 people
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes.
- Trial name
- COMBINE 1 (NCT05352815)
- Testing
- IcoSema, Insulin icodec
- Where
- 281 sites in United States, Australia and 20 more
- Volunteers
- 1,291 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together
This study will look at a new medicine, called IcoSema, for treatment of type 2 diabetes. IcoSema is a combination of a new insulin, called insulin icodec, and a GLP-1 receptor analogue, called semaglutide.
- Trial name
- NCT05435677
- Testing
- IcoSema, insulin icodec, semaglutide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels.
- Trial name
- PIONEER REAL (NCT05443568)
- Testing
- Oral semaglutide
- Where
- Israel
- Volunteers
- 155 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
This study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- STEP7 (NCT04251156)
- Testing
- Semaglutide
- Where
- 33 sites in Brazil, China and 2 more
- Volunteers
- 375 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 2 (NCT03552757)
- Testing
- Semaglutide 1.0 mg, Semaglutide 2.4 mg
- Where
- 147 sites in United States, Argentina and 11 more
- Volunteers
- 1,210 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.
- Trial name
- PIONEER 4 (NCT02863419)
- Testing
- semaglutide, liraglutide
- Where
- 108 sites in United States, Croatia and 11 more
- Volunteers
- 711 people
- Sponsor
- Novo Nordisk A/S